Revenue
Cost
Profit
| Item | Category | Value | YoY |
|---|---|---|---|
| Net sales | revenue | 1.65B | 16.70% |
| Other operating income (expense), net | revenue | 14.20M | -25.65% |
| Gross profit | profit | 1.29B | 15.74% |
| Cost of sales | cost | 362.60M | 20.23% |
| Aggregate | revenue | 1.30B | 15.04% |
| Other non-operating income, net (note7) | revenue | 71.50M | 2650.00% |
| Investment income, interest | revenue | 33.50M | -8.22% |
| Segment operating income | profit | 477.60M | 20.97% |
| Selling, general, and administrative expenses | cost | 522.20M | 12.13% |
| Research and development expenses | cost | 263.30M | 3.42% |
| Certain litigation expenses | cost | 37.10M | 240.37% |
| Aggregate | revenue | 582.60M | |
| Income from continuing operations before provision for income taxes | profit | 459.00M | 5.78% |
| Loss on impairment (note 6) | cost | 123.60M | |
| Income from continuing operations, net of tax | profit | 380.70M | 4.70% |
| Provision for income taxes | cost | 78.30M | 11.38% |
| Net income | profit | 380.70M | 6.82% |
| Net income attributable to edwards lifesciences corporation | profit | 380.70M | 6.34% |
| Segment | Value | YoY |
|---|---|---|
| United States | 937.60M | 11.77% |
| Europe | 442.60M | 29.49% |
| Rest Of World | 177.80M | 18.38% |
| Japan | 90.60M | 10.76% |
| Segment | Value | YoY |
|---|---|---|
| Transcatheter Aortic Valve Replacement | 1.20B | 14.40% |
| Surgical | 276.20M | 10.08% |
| Transcatheter Mitral And Tricuspid Therapies | 175.10M | 52.00% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Cash and cash equivalents | assets | 2.45B | |
| Short-term investments (note 5) | assets | 1.23B | |
| Inventories (note 2) | assets | 1.12B | |
| Accounts receivable, net of allowances of $15.6 and $15.0, respectively | assets | 775.70M | |
| Other current assets | assets | 329.50M | |
| Other receivables | assets | 197.30M | |
| Prepaid expenses | assets | 135.70M | |
| Total current assets | assets | 6.23B | |
| Property, plant, and equipment, net | assets | 1.82B | |
| Goodwill | assets | 1.82B | |
| Other intangible assets, net | assets | 1.23B | |
| Deferred income taxes | assets | 1.10B | |
| Other assets (note 2) | assets | 738.90M | |
| Long-term investments (note 5) | assets | 285.60M | |
| Operating lease right-of-use assets | assets | 99.30M | |
| Total assets | assets | 13.32B | |
| Total liabilities | liabilities | 2.99B | |
| Total edwards lifesciences corporation stockholders' equity | equity | 10.33B | |
| Treasury stock, common, value | equity | 7.51B | |
| Accumulated other comprehensive loss (note 13) | equity | 221.30M | |
| Total current liabilities | liabilities | 1.41B | |
| Long-term debt | liabilities | 598.50M | |
| Uncertain tax positions | liabilities | 555.40M | |
| Other liabilities | liabilities | 350.70M | |
| Operating lease liabilities | liabilities | 80.10M | |
| Aggregate | equity | 18.06B | |
| Accrued and other liabilities (note 2) | liabilities | 1.20B | |
| Accounts payable | liabilities | 181.10M | |
| Operating lease liabilities | liabilities | 24.30M | |
| Retained earnings | equity | 14.62B | |
| Additional paid-in capital | equity | 2.78B | |
| Common stock, value, issued | equity | 660.00M |
| Item | Value |
|---|---|
| Net income | 380.70M |
| Loss on impairment (note 6) | 123.60M |
| Stock-based compensation (note 10) | 45.40M |
| Income taxes | 41.90M |
| Depreciation and amortization | 40.90M |
| Increase (decrease) in deferred income taxes | 9.40M |
| Non-cash operating lease cost | 6.50M |
| Gain (loss) on investments | 3.50M |
| Other noncash income (expense) | 500000 |
| Increase (decrease) in inventories | -1.60M |
| Increase (decrease) in prepaid expense and other assets | -8.70M |
| Increase (decrease) in other operating assets and liabilities, net | -18.10M |
| Intellectual property agreement accrual | -50.00M |
| Business combination, achieved in stages, preacquisition equity interest in acquiree, remeasurement, gain (loss) | -65.20M |
| Increase (decrease) in accounts and other receivables | -117.90M |
| Accounts payable and accrued liabilities | -347.10M |
| Item | Value |
|---|---|
| Proceeds from available-for-sale investments (note 5) | 710.10M |
| Proceeds from held-to-maturity investments (note 5) | 12.50M |
| Payment for (proceeds from) other investing activity | -300000 |
| Payments to acquire interest in subsidiaries and affiliates | -6.30M |
| Payments to acquire held-to-maturity securities | -12.50M |
| Payments to acquire businesses, net of cash acquired, excluding options | -35.10M |
| Payments to acquire receivables | -55.20M |
| Payments to acquire property, plant, and equipment | -64.90M |
| Payments to acquire debt securities, available-for-sale | -641.10M |
| Item | Value |
|---|---|
| Proceeds from stock plans | 68.90M |
| Other | 1.70M |
| Payments for equity forward contract related to accelerated share repurchase agreement | -100.00M |
| Payments for repurchase of common stock | -421.80M |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 2.94B |
| Cash and cash equivalents, end of period | 2.45B |
Instantly decode complex 10-K and 10-Q data. Explore interactive Sankey diagrams for income and balance sheets, and intuitive waterfall charts for cash flows.
Search for a company and select a report on the left panel.
Request Stock Support